Fluorizon - Molecular Radiolabeling Service

Fluorizon’s Molecular Radiolabeling Services

Fluorizon is a contract research organisation (CRO) which provides services for the preparation and preclinical evaluation of radiolabeled molecules (radiopharmaceuticals) to international (radio)pharmaceutical companies. Fluorizon’s unique radiolabeling technology allows molecules (e.g. drug candidates) to be rapidly radiolabeled in high yields. Molecular radiolabeling allows customers to gain key insights into how their molecules perform in cellular assays or in small animal models. The data we provide to customers can be used for radiopharmaceutical development and to accelerate drug development pipelines. Fluorizon cooperates exclusively with the Institute of Radiopharmaceutical Cancer Research at the Helmholtz-Zentrum Dresden-Rossendorf and the Department of Radiopharmaceutical and Chemical Biology for PET imaging experiments.

Diagnostic Medical Imaging

Work at the Institute for Radiopharmaceutical Cancer Research

[borlabs-cookie id="youtube" type="content-blocker"] [/borlabs-cookie]

Positron emission tomography (PET) imaging is a non-invasive medical imaging technique used in combination with magnetic resonance imaging (MRI) or single-photon emission computed tomography (SPECT) in hospitals for the diagnosis of a number of clinical disorders. PET imaging is commonly used in cancer diagnostics, where the size and spread of the cancer is visualized.

Radiopharmaceuticals (radiolabeled molecules) are required for PET imaging experiments, and provide high resolution PET images where the pharmacokinetic and pharmacodynamic (PK/PD) pathways of the radiopharmaceutical can be visualized in real-time. Radiopharmaceuticals are radioactive molecules which must be rapidly prepared using specialized equipment and infrastructure prior to a PET imaging experiment.

Radiopharmaceuticals for Drug Development

PET imaging experiments may be used as an invaluable methodology to support drug development. In vitro and in vivo experiments using radiopharmaceuticals provide information concerning a drug candidate’s absorption, distribution, metabolism and excretion (ADME). PET images may also be used to determine drug-target interaction and blood brain barrier (BBB) penetration. Radiopharmaceuticals used for biodistribution studies are currently the gold standard approach in the analysis of the pharmacokinetics and the quantification of relative tissue concentrations.

Learn more about the Department of Medical Radiochemistry at HZDR

What we offer

Molecular Radiolabeling: We can transform molecules into radiopharmaceuticals with a variety of radionuclides depending on the desired application. Radionuclides including copper-64 ([⁶⁴Cu]), fluorine-18 ([¹⁸F], gallium-68 ([⁶⁸Ga]) and iodine-123 ([¹²³I]) are readily available for the radiolabeling of molecules.
In vitro Assays: Radiopharmaceutical stability, specificity and binding to a biological target can be evaluated using a number of cellular assays. Real-time binding experiments using radiopharmaceuticals on live cells can be used to determine the binding mechanism, affinity and kinetics.
In vivo Experiments: Following in vitro validation, a radiopharmaceutical may be visualized using PET or SPECT imaging in a small animal model. Pharmacokinetics (PK) and biodistribution (ADME) studies may be performed using clinically healthy mice. More complex tumor models may also be considered on demand.

Discuss your requirements with us!

Fluorizon is a future spin-off company from Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, 01328 Dresden

mail: austin.craig@fluorizon.com